AKORN INC

Akorn Inc, operating within SIC 2834 (Pharmaceutical Preparations), develops and manufactures a portfolio of generic and branded ophthalmic, injectable, and topical treatments that supply hospitals, surgical centers, physicians’ offices, and retail pharmacies seeking cost-effective alternatives to higher-priced therapies; the company also supports specialty pharmacies catering to chronic care and long-term treatment regimens. With a focus on sterile dosage forms, ophthalmology drops, and dermatology creams, Akorn enables healthcare providers to deliver familiar, approved therapies while managing tight formularies and reimbursement pressures. Its workstream includes large-scale sterile compounding, packaging, and distribution orchestration to support patients, clinicians, and institutional buyers across the U.S. Despite the undefined latest filing, Akorn remains subject to FDA scrutiny around cGMP compliance, pricing pressure from commercial payers, potential supply-chain disruptions, and generic competition in crowded therapeutic classes, making regulatory vigilance and quality systems critical to its market position, CIK 3116. View live SEC filings on Earnings Feed.

Source: Earnings Feed research · last updated 11/24/2025